Russia, Moscow, June 4, 2018 - AbbVie, a research-based global biopharmaceutical company, and
There are 943,999 people living with HIV in Russia now. About 346,000 people constantly receive antiretroviral therapy (ART). The therapy coverage is steadily increasing as stipulated by the government and public goals to combat the HIV/AIDS epidemic in Russia. The number of patients receiving ART has increased by 2.76 times compared to 2012.
"Completion of the technology transfer and organization of the full cycle production of the drug for HIV/AIDS treatment is an important stage in implementation of Pharma-2020 Strategy," said Vasily Ignatyev, General Director,
"At AbbVie, we are committed to make remarkable impact on patients' lives. Antiretroviral therapy helps patients to live normal live, control the disease, and restrains epidemic," said Anthony Wong, Regional Vice-President, Russia, Ukraine & CIS, AbbVie. "The full cycle production is a step forward to improve access to antiretroviral therapy for Russian patients".
AbbVie has been an active participant of the health care industry in our country for over 40 years now (as part of Abbott prior to 2013) and a strategic partner of the government in modernization of the medical assistance system and development of the Russian pharmaceutical market. Localization of AbbVie drugs is one of important company activities in Russia. Such projects help improve access to innovative therapy and correspond to the top priorities of the government health care policy.
The following steps have been successfully implemented under the Kaletra® localization project in Russia: additional installation of equipment at
AbbVie is a global, research-driven biopharmaceutical company committed to developing innovative advanced therapies for some of the world's most complex and critical conditions. The company's mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience. In more than 75 countries, AbbVie employees are working every day to advance health solutions for people around the world. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook.
 - Excerpt from the speech of Olga Golodets, Deputy Chair of the Russian Government, at the 6th Eastern Europe and Central Asia HIV/AIDS Conference on April 18, 2018 http://government.ru/news/32325/